Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBITDA Margin (2020 - 2026)

Maxcyte has reported EBITDA Margin over the past 6 years, most recently at 678.42% for Q4 2025.

  • Quarterly EBITDA Margin fell 103239.0% to 678.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 29.45% through Dec 2025, down 1308.0% year-over-year, with the annual reading at 24.26% for FY2025, 1321.0% down from the prior year.
  • EBITDA Margin was 678.42% for Q4 2025 at Maxcyte, down from 191.71% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 353.96% in Q4 2024 and troughed at 678.42% in Q4 2025.
  • The 5-year median for EBITDA Margin is 147.45% (2021), against an average of 161.89%.
  • Year-over-year, EBITDA Margin soared 88023bps in 2024 and then plummeted -103239bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 425.03% in 2021, then skyrocketed by 93bps to 29.01% in 2022, then tumbled by -1714bps to 526.27% in 2023, then surged by 167bps to 353.96% in 2024, then crashed by -292bps to 678.42% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's EBITDA Margin are 678.42% (Q4 2025), 191.71% (Q3 2025), and 154.44% (Q2 2025).